, Volume 78, Issue 10, pp 1057–1062 | Cite as

Anlotinib: First Global Approval

  • Yahiya Y. SyedEmail author
AdisInsight Report


Jiangsu Chia-Tai Tianqing Pharmaceutical and Advenchen Laboratories are co-developing anlotinib (Focus V®) for the treatment of advanced cancer. Anlotinib is an oral small molecule inhibitor of multiple receptor tyrosine kinases, with a broad spectrum of inhibitory effects on tumour angiogenesis and growth. Anlotinib is approved in China for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have undergone progression or recurrence after ≥ 2 lines of systemic chemotherapy. Anlotinib is also undergoing phase II and/or III clinical development for various sarcomas and carcinomas in China, USA and Italy. This article summarizes the milestones in the development of anlotinib leading to this first approval for NSCLC.


Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflicts of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Yahiya Y. Syed is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.


  1. 1.
    Regad T, Targeting RTK. Signaling pathways in cancer. Cancers. 2015;7(3):1758–84.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9(1):105.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Syrigos KN, Saif MW, Karapanagiotou EM, et al. The need for third-line treatment in non-small cell lung cancer: an overview of new options. Anticancer Res. 2011;31(2):649–59.PubMedGoogle Scholar
  4. 4.
    Chia Tai Tianqing Pharmaceutical. Anlotinib hydrochloride capsules. 2018. Accessed 29 May 2018.
  5. 5.
    Advenchen Laboratories. 2018. Accessed 30 May 2018.
  6. 6.
    Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018;109(4):1207–19.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lin B, Song X, Yang D, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRbeta and FGFR1. Gene. 2018;654:77–86.CrossRefPubMedGoogle Scholar
  8. 8.
    Taurin S, Yang CH, Reyes M, et al. Endometrial cancers harboring mutated fibroblast growth factor receptor 2 protein are successfully treated with a new small tyrosine kinase inhibitor in an orthotopic mouse model. Int J Gynecol Cancer. 2018;28(1):152–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Han B, Li K, Wang Q, et al. Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2017;18(Suppl 1):S3.CrossRefGoogle Scholar
  10. 10.
    Han B, Li K, Wang Q, et al. Efficiency of anlotinib as 3rd line treatment in patients with different EGFR gene status, an exploratory subgroup analysis of ALTER0303 trial [abstract no. P3.03-006]. J Thorac Oncol. 2017;12(11 Suppl 2):S2275.CrossRefGoogle Scholar
  11. 11.
    Han B, Zhao Y, Li K, et al. Blood samples NGS for baseline molecular signature of anotinib treated advanced NSCLC patients in ALTER0303 trial [abstract no. P3.03-017]. J Thorac Oncol. 2017;12(11 Suppl 2):S2279.CrossRefGoogle Scholar
  12. 12.
    Li K, Wang J, Han B, et al. Impact factor analysis for efficacy and prognosis of anlotinib in NSCLC as third-line treatment: data from trial alter 0303 [abstract no. P3.01-087]. J Thorac Oncol. 2017;12(11 Suppl 2):S2236.CrossRefGoogle Scholar
  13. 13.
    Li K, Wang J, Wang X, et al. Level of activated circulating endothelial cells to predict progression-free survival of anlotinib treatment in patients with NSCLC: analysis on ALTER-0303 study [abstract no. e20530]. J Clin Oncol. 2017;35(15 Suppl):e20530.CrossRefGoogle Scholar
  14. 14.
    Han B, Li K, Zhao Y, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018;118(5):654–61.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhou AP, Bai Y, Song Y, et al. Anlotinib in metastatic renal cell carcinoma (mRCC) with a previous anti-VEGFR TKI: preliminary results from a multicenter, phase II trial [abstract no. e16082]. J Clin Oncol. 2016;34(15 Suppl):e16082.CrossRefGoogle Scholar
  16. 16.
    Chi Y, Sun Y, Cai J, et al. Phase II study of anlotinib for treatment of advanced soft tissues sarcomas [abstract no. 11005]. J Clin Oncol. 2016;34(Suppl 15):11005.CrossRefGoogle Scholar
  17. 17.
    Zhou AP, Ma J, Bai Y, et al. Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): preliminary results from a randomized phase II clinical trial [abstract no. 4565]. J Clin Oncol. 2016;34(15 Supplement):4565.CrossRefGoogle Scholar
  18. 18.
    Sun Y, Chi Y, Tang P, et al. Phase II study of anlotinib for treatment of advanced medullary thyroid carcinoma [abstract no. 6015]. J Clin Oncol. 2016;34(15 Suppl):6015.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations